NCT00989404View on ClinicalTrials.gov

Crossover Study to Investigate the Safety, Tolerability, and Pharmacokinetics of Repeat Dose Zanamivir/Placebo Via Devices Administered Twice Daily for 5 Days

PHASE1CompletedINTERVENTIONAL
Enrollment

18

Participants

Timeline

Start Date

October 12, 2009

Primary Completion Date

December 7, 2009

Study Completion Date

December 7, 2009

Conditions
Influenza A Virus, H1N1 Subtype
Interventions
DRUG

Zanamivir

Rotahaler placebo 10mg BID 5 days

DRUG

Zanamivir

Rotahaler Zanamivir 10mg BID 5 days

DRUG

Zanamivir

Diskhaler Zanamivir 10mg BID 5 days

Trial Locations (1)

55404

GSK Investigational Site, Minneapolis

Sponsors

Lead Sponsor

GlaxoSmithKline
All Listed Sponsors
lead

GlaxoSmithKline

INDUSTRY

NCT00989404 - Crossover Study to Investigate the Safety, Tolerability, and Pharmacokinetics of Repeat Dose Zanamivir/Placebo Via Devices Administered Twice Daily for 5 Days | Biotech Hunter | Biotech Hunter